Company / Income Tax
ELITE PHARMACEUTICALS INC /NV/ Income Tax History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Income Tax
$4.3M
FY2024
5-year range
-$19.6M / $4.3M
FY2020-FY2024
Trend
+121.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Income Tax has fluctuated over the past 8 years, ranging from -$20M in FY2023 to $4M in FY2024.
Based on SEC 10-K filings.
$4M in FY2024.
Increased from $424,028 to $4M over the past 2 years.
Income Tax over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, income tax increased 121.7% year-over-year.
- Lowest income tax in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Income TaxValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $4.3M | +121.7% |
| FY2023 | -$19.6M | -4733.1% |
| FY2022 | $424.0K | +124.4% |
| FY2021 | -$1.7M | - |
| FY2020 | - | - |
| FY2019 | -$676.0K | +0.0% |
| FY2018 | -$676.0K | +35.4% |
| FY2017 | -$1.0M | +44.0% |
| FY2016 | -$1.9M | -258.8% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026